IGMPI India

October 7, 2015

October 7, 2015

PAN Drugs receives warning letter from USFDA

USFDA has recently issued a warning letter to PAN drugs Vadodara based plant due to significant deviations from good manufacturing practices.

MHRA issues recall notice of Lacri-Lube eye ointment

The Medicines and Healthcare Products Regulatory Agency (MHRA) has issued a recall notice to Allergen Limited. The recall notice relates to 5g and 3.5g pack sizes of

Another Import Ban for Polydrug Laboratories

USFDA (Food and Drug Administration) issues import ban for products manufactured by Polydrug Laboratories. It was issued on Sept. 11, 2015 for

Health Canada lifts its ban from two Apotex facilities in India

Health Canada has lifted its ban from Apotex two Indian facilities. Canada’s drug regulator reinspected the two plants in June and determined

33 drugs were found to be of not of standard quality during Surprise inspection

Recently Karnataka drug control department had conducted surprise inspections to pick up drug samples at random. The drug test labs have issued their result.

Vivimed Labs successfully completes USFDA inspection of its manufacturing facility

Vivimed Labs has recently successfully completed inspection of its API manufacturing facility in Spain. After the completion of inspection Vivimed said “the USFDA inspectors concluded

GMP News & Guidelines Archives:

VIEW HERE

Health Canada gives a nod for Ranbaxys anti-dementia drug

The drug company, Ranbaxy, which has been under scanners of global health regulators for various GMP related issues, now seems to be announcing some good news. The company recently announced that it has received a green signal from Health Canada, for marketing the generic version of Pfizers Aricept drug. This drug is intended for treating dementia in Alzheimers disease.

Health Canada has extended its approval to Ranbaxy Pharmaceuticals Canada Inc (RPCI) with the permission to manufacture and sell Aricept tablets that contain donepezil hydrochloride of strengths 5mg and 10mg.

As stated by the Ranbaxy Canada officials, the manufacturing of the finished dosage of these drug tablets would be manufactured at Ohm laboratories at New Jersey in USA. The company is very positive about this approval and foresees that this launch can prove to be beneficial to the patients, medical professionals as well as the company as a whole.